Anish Patel - Mar 7, 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Mar 7, 2025
Transactions value $
-$142,936
Form type
4
Date filed
3/11/2025, 05:18 PM
Previous filing
Feb 10, 2025
Next filing
Apr 9, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Sale -$143K -6.67K -2.02% $21.44 323K Mar 7, 2025 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").
F2 This transaction was executed in multiple trades at prices ranging from $20.99 to $22.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The shares are held by The Patel / Dong Family Trust.